Iron status in piglets at three days of age and at weaning and possible seasonal effects on the blood haemoglobin levels in a Swedish outdoor pig-producing farm

The Epidemiology of Hemoglobin Levels in Patients With Type 2 Diabetes

More Effective Route of Treatment for Iron Deficiency Anemia in Pregnancy Intravenous Vs Oral Iron

KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD

To assess the usefulness of the complete blood count (CBC) and the reticulocyte count in the evaluation of adult patients with acute vasoocclusive sickle-cell crisis (SCC) presenting to the ED. A 2-part study was performed. Part 1 was retrospective chart review of patients with a sole ED diagnosis of acute SCC. Part 2 was a prospective evaluation of consecutive patients presenting in SCC. In both parts of the study, patients with coexisting acute disease were excluded. The remaining patients were divided into 2 groups: admitted and released. The mean values for white blood cell (WBC) count, hemoglobin (Hb) level, and reticulocyte count were compared. In Part 2, the change (delta) from the patient's baseline in WBC count, Hb level, and reticulocyte count also was determined. Data were analyzed by 2-tailed Student's t-test. Part 1: There was no difference between the admitted (n = 33) and the released (n = 86) groups in mean WBC count (p = 0.10), Hb level (p = 0.25), or reticulocyte count (p = 0.08). Part 2: There was no difference between the admitted (n = 44) and the released (n = 160) groups in mean Hb level (p = 0.88), reticulocyte count (p = 0.47), delta Hb level (p = 0.88), and delta reticulocyte count (p = 0.76). There was a difference in mean WBC counts (15.8 +/- 4.9 x 10(9)/L admitted vs 12.8 +/- 4.9 x 10(9)/L released, p = 0.003) and delta WBC counts (5.1 +/- 4.6 x 10(9)/L admitted vs 1.8 +/- 4.6 x 10(9)/L released, p < 0.002). Determination of the Hb level and the reticulocyte count do not appear useful in the evaluation of acute SCC in the ED. Admission decisions appear associated with elevations in the WBC count. Further study is required to determine the true value of the WBC count in such decisions.

In the treatment of preoperative anemia, which is associated with increased postoperative morbidity, iron supplementation can replace blood transfusion and erythropoiesis-stimulating agents. The aim of this study was to assess the efficacy of preoperative intravenous (IV) iron infusion in optimizing hemoglobin (Hb) levels in anemic colorectal cancer patients. A retrospective cohort study was performed on patients who underwent surgery for colorectal cancer between 2010 and 2016 in a single teaching hospital. The primary outcome measure, the change in Hb level, was assessed by comparing anemic patients receiving usual care (UC; i.e. no iron therapy and no blood transfusion) with anemic patients receiving IV iron therapy (no blood transfusion). A total of 758 patients with colorectal cancer were eligible, of whom 318 (41.9%) had anemia. The IV and the UC groups included 52 and 153 patients with mean Hb levels at diagnosis of 6.3 and 6.9 mmol/L, respectively. In the IV group, preoperative Hb level was significantly increased compared to the UC group (0.65 mmol/L vs. 0.10 mmol/L, p < 0.001). High increase in Hb level after iron infusion was associated with initial higher transferrin and lower ferritin levels (high vs. poor responders: median transferrin 2.9 g/L vs. 2.7 g/L, median ferritin 12 µg/L vs. 27 µg/L). Implementation of IV iron therapy in anemic colorectal cancer patients leads to a distinct increase of preoperative Hb level. IV iron therapy is most effective in patients presenting with more severe anemia, and with higher transferrin and lower ferritin levels, markers for an absolute iron deficiency (ID), compared to functional ID.

Introduction: Anemia during pregnancy is an important public health problem and is associated with a number of maternal and fetal complications. Intravenous iron sucrose (IVIS) has been reported to be safe and efficacious in raising the hemoglobin (Hb) level among pregnant women. However, most of the studies were conducted in controlled research settings, and there is a paucity of data on the effectiveness when IVIS is given as routine therapy in public health facilities. The objective of this study was to estimate the change in mean Hb level four weeks after the last dose of IVIS infusion in pregnant women with moderate to severe anemia in a public healthcare setting.Methods: Records of pregnant women having moderate anemia (Hb level: 7.0-9.9 gm/dL), who received IVIS in calculated dose during routine antenatal care between 1 January 2018 and 31 July 2018, were reviewed. Data were analyzed using STATA version 13 software (StataCorp LLC, College Station, TX). Hb levels before the start of the therapy (baseline) and four weeks after the last infusion (endline) were compared. A value of p < 0.05 was considered statistically significant.Results: The mean (±SD) Hb level increased from 8.5 (±0.88) gm/dL at baseline to 10.3 (±1.24) gm/dL four weeks after the last dose of IVIS infusion. The mean (±SD) increase in Hb level was 1.7 (±1.29) gm/dL (95% CI: 1.57, 1.87). The change from moderate and severe anemia to normal Hb levels was observed in 28.4% and 28.6% of women, respectively.Conclusion: IVIS therapy is effective in improving Hb levels when given as routine therapy in a secondary level public healthcare facility.

Background: Pregnancy is a very important period, the state of the mother and fetus are related to one another. While pregnant women are often found to have iron deficiency anemia. One of the efforts to overcome the problem of anemia in pregnant women is by giving iron supplements. However, in Riau Province pregnant women who received FE3 decreased, namely in 2018 as much as 79% decreased to 65% in 2019. Therefore, an educational method is needed to increase knowledge, and adherence to taking iron supplements, and hemoglobin (Hb) levels in pregnant women. Objectives: To increase knowledge and adherence of taking iron supplements and hemoglobin (Hb) levels in pregnant women. Methods: This study is a pre-experimental study with one group pretest and post-test to evaluate the effect of nutrition education with video media on knowledge, adherence to taking iron supplements, and Hb levels in late-trimester pregnant women. The educational videos include material on the importance of taking iron supplements, how to consume them, and balanced nutrition for pregnant women. Result: There is a statistically significant difference between the knowledge and the adherence of pregnant women taking iron supplements before and after treatment or intervention with a significance value of 0.000 (&lt;0.05). Changes in Hb levels before and after treatment or intervention in the form of Educational Video for Iron Supplements (TTD) and Nutrition for Pregnant Women did not show a statistically significant difference with a significance value of 0.085 (&gt; 0.05).Conclusion: Educational videos on iron supplements and nutrition for Pregnant Women affect knowledge and adherence of pregnant women taking iron supplements.

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

Stimulating erythropoiesis before hip fracture repair for reducing blood transfusion: should we change the hemoglobin cutoff level for defining anemia in females?

Iron-Replete Hemodialysis Patients Do Not Require Higher EPO Dosages When Converting From Subcutaneous to Intravenous Administration: Results of the Italian Study on Erythropoietin Converting (ISEC)

BACKGROUND: Anemia cases in pregnant women in Indonesia are still high because pregnant women do not routinely take iron supplements or often referred as Tablet Tambah Darah because of the side effects it causes. An alternative to this problem is the intravenous administration of iron sucrose. AIM: The purpose of this study was to determine differences in ferritin and hemoglobin (Hb) levels before and after administration of iron sucrose injection to pregnant women in the second or third trimester at Araskabu Public Health Center, Deli Serdang. METHODS: This is an analytical study with a Quasi-Experimental Pre-Post Design for Second or Third Trimester Pregnant Women at Araskabu Public Health Center, Deli Serdang which was carried out in April 2022 by blood sampling and administration of iron sucrose injection intravenously, and then blood sampling was repeated 14 days after the injection in May 2022. The subjects in this study were 25 pregnant women aged 20–40 years who had antenatal care selected using the Consecutive Sampling technique. The difference in the mean of ferritin and Hb was analyzed using the paired t-test if the data are normally distributed and the Wilcoxon test if the data are not normally distributed. The results were significant if p &lt; 0.001. The Mann–Whitney and Kruskal–Wallis tests were used to examine the difference between two or more sample groups. The results of the analysis were significant if p &lt; 0.050. RESULTS: The mean ferritin level before administration of iron sucrose injection to pregnant women in this study was 18.97 ± 8.284 g/L and the mean ferritin level after iron sucrose injection was 98.95 ± 18.878 g/L. The mean increase in ferritin levels after injection of iron sucrose was 79.97 ± 19.77 g/L. The mean Hb level before administration of iron sucrose injection to pregnant women in this study was 10.13 ± 0.386 g/dL and the mean Hb level after administration was 12.01 ± 0.723 g/dL. The mean increase in Hb levels after injection of iron sucrose was 1.88 ± 0.68 g/dL. CONCLUSIONS: Iron sucrose injection can significantly increase ferritin and Hb levels.

A cross-sectional study was carried out to evaluate the haemoglobin (Hb) levels during pregnancy in Bindura District of Zimbabwe. The main objective was to establish the effect of varying age and parity on Hb levels in pregnant women. Blood samples were taken from 60 pregnant women visiting Shashi Private Hospital for antenatal care for 2 weeks. The ages, parity and physical addresses of the participants were recorded. The highest mean Hb level recorded was 11.350 g/dL in the 35–39 years category and 11.337g/dL for the para 0 gravida 4. There were no significant differences in the mean Hb levels across the different age groups and the parity groups. However, the mean Hb levels were generally low. Hb levels need to be checked and rectified at the early stages of pregnancy to attain the required Hb level throughout pregnancy through improved diet and iron supplementation.

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

BackgroundErythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections (Recombinant Human Erythropoietin injection, rHuEPO) when maintaining hemoglobin (Hb) levels within the target range (10.0–12.0 g/dL) for the treatment of renal anemia.MethodsNinety‐five patients were enrolled in this study from April 15, 2013 to April 10, 2014 at 25 sites. In this study, patients (n = 95) aged 18–70 years were randomized into a once per week intravenous darbepoetin alfa group (n = 56) and a twice or three times per week intravenous epoetin alfa group (n = 39) for 28 weeks, who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease (CKD) and were undergoing hemodialysis or hemofiltration with ESA‐naive (erythropoiesis stimulating agent‐naive). The primary efficacy profile was the mean Hb level (the non‐inferiority margin was −1.0 g/dL, week 21–28); the secondary efficacy profiles were the Hb increase rate (week 0–4), the target Hb achievement cumulative rate and time, the change trends of the Hb levels, and the target Hb maintenance ratio. Adverse events (AEs) were observed and compared, and the efficacy and safety were analyzed between the two treatment groups. Additionally, the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period. SAS® software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators.ResultsThe mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group, respectively; the difference of the lower limits of the 95% confidence intervals (CI) between the two groups was 0.1 g/dL (>−1.0 g/dL), and non‐inferiority was proven; the Hb levels started to increase in the first four weeks at a similar increase rate; no obvious differences were observed between the groups in the target Hb achievement cumulative rates, and the Hb levels as well as the target Hb level maintenance rate changed over time. The incidence of AEs was 62.5% in the darbepoetin alfa group and 76.9% in the epoetin alfa group. All the adverse events observed in the study were those commonly associated with hemodialysis.ConclusionDarbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.

Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study